Committee hears bill to exempt FDA‑approved crystalline polymorph psilocybin from Kansas Schedule I
Witnesses and committee members discussed House Bill 2218, which would amend Kansas law to exclude FDA‑approved pharmaceutical crystalline polymorph psilocybin from the Schedule I controlled substances list and add such FDA‑approved products to Schedule IV once federal approvals and state certification occur.
The full story
The Committee on House Health and Human Services held a hearing on House Bill 2218, a bill that would amend the Kansas Uniform Controlled Substances Act to exclude an FDA‑approved pharmaceutical composition of crystalline polymorph psilocybin from the Schedule I definition and to add any such FDA‑approved product to Schedule IV after federal approvals and state certification.
Sign up to keep reading.
Your free newsletter brings you what your city council, county, and school board discussed and decided.
Keep reading for free
Create a free account to finish this story and see the video, transcript and key details.
Continue with GoogleContinue with emailAlready have an account? Log in